πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

3,067 results for β€œHospital” Clear

  1. 0.9% sodium chloride

    The First People's Hospital of Lianyungang

    Kidney Disease, Chronic

    phase 2 small molecule active

    1 trial

  2. 12.5mg sunitinib with Cisplatin and Gemcitabine

    Hospital Authority, Hong Kong

    Nasopharyngeal Carcinoma

    phase 2 small molecule completed

    1 trial

  3. 16mg，KB

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Sepsis

    phase 2 small molecule active

    1 trial

  4. 177Lu-DOTA-EB-FAPI radionuclide therapy

    The First People's Hospital of Lianyungang

    Refractory Solid Tumor

    phase 2 small molecule completed

    1 trial

  5. 18F-92

    The First People's Hospital of Lianyungang

    Alzheimer's Disease

    phase 2 small molecule active

    1 trial

  6. 1ΞΌg/ml ESAT6-CFP10 and tuberculin purified protein derivative

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Tuberculosis

    phase 2 mab completed

    1 trial

  7. 2 cycles of combined drug induction therapy: every 3 weeks for 2 cycles; After ,synchronous radiotherapy and chemotherapy combined immunotherapy

    The First People's Hospital of Lianyungang

    Cervical Cancer Stage IVA

    phase 2 other active

    1 trial

  8. 225Ac-LNC1011

    The First People's Hospital of Lianyungang

    Prostate Cancer

    phase 2 small molecule active

    1 trial

  9. 3D hypoxia-preconditioned UC-MSC group

    The First People's Hospital of Lianyungang

    Severe Aplastic Anemia (SAA)

    phase 2 small molecule active

    1 trial

  10. 5% MInoxidil milky lotion

    Hospital Authority, Hong Kong

    Objective (Goal)

    phase 2 small molecule active

    1 trial

  11. 5-Fluorouracil

    Hospital Authority, Hong Kong

    Cancer (Advanced Stage)

    phase 2 small molecule active

    1 trial

  12. 5ΞΌg/ml ESAT6-CFP10

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Tuberculosis

    phase 2 mab completed

    1 trial

  13. 5ΞΌg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Tuberculosis

    phase 2 mab completed

    1 trial

  14. 68Ga-DOTATATE and 68Ga-FAPI

    The First People's Hospital of Lianyungang

    Tumor Positron-Emission Tomography

    phase 2 small molecule completed

    1 trial

  15. 68Ga-FAP-CHX

    The First People's Hospital of Lianyungang

    Tumor

    phase 2 small molecule active

    1 trial

  16. 68Ga-G21

    The First People's Hospital of Lianyungang

    Prostate Cancer (Adenocarcinoma)

    phase 2 small molecule active

    1 trial

  17. 68Ga-NODAGA-SNA006

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Cancer

    phase 2 small molecule active

    1 trial

  18. 68Ga-NY104 PET/CT

    Peking University Third Hospital

    Clear Cell Renal Cell Carcinoma

    phase 2 other active

    1 trial

  19. 68Ga-NY104 PET/CT

    The First People's Hospital of Lianyungang

    Clear Cell Renal Cell Carcinoma

    phase 2 small molecule active

    1 trial

  20. 68Ga-Pentixafor

    Peking University Third Hospital

    Cushing s Syndrome

    phase 2 small molecule active

    1 trial

  21. A MULTICENTER, SEEKING SIGNAL, RANDOMISED, OPEN-LABEL PHASE II OF RELATLIMAB AND NIVOLUMAB VS NIVOLUMAB ALONE IN LOCALLY ADVANCED CERVICAL CANCERS

    Ningbo Cancer Hospital

    Patients with a histilogically confirmed diagnosis of cervical squamous or adenosquamous carcinoma stage IB3 if N>=1 or II to IVA with any N stage according to FIGO 2018 and no evidence of metastatic disease (M0), without any prior anti-cancer treatment.

    phase 2 other active

    1 trial

  22. A phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the safety, tolerability, and efficacy of S-337395 in symptomatic nonhospitalized adults with respiratory syncytial virus who are at high risk of progression to severe disease

    Shionogi B.V.

    Respiratory Syncytial Virus

    phase 2 other active

    1 trial

  23. ADCETRIS 50 mg powder for concentrate for solution for infusion, DACARBAZINE , DOXORUBICIN , DEXAMETHASONE , VINBLASTINE , CYCLOPHOSPHAMIDE , ETOPOSIDE

    Ningbo Cancer Hospital

    Advanced stage Hodgkin Lymphoma

    phase 2 small molecule active

    1 trial

  24. ADSC01

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Connective Tissue Diseases

    phase 2 mab active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources